Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 3/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7523239 | 0.88 | MAPT (0.43) | MAPTTP53ALDH1A1KDM4EKMT2A | |
| SCHEMBL7517503 | 0.88 | KDM4E (0.43) | MAPTTP53ALDH1A1KDM4EKMT2A | |
| SCHEMBL10305490 | 0.88 | MAPT (0.41) | MAPTTP53ALDH1A1KDM4EKMT2A | |
| SCHEMBL7517913 | 0.88 | POLB (0.41) | MAPTTP53ALDH1A1KDM4EKMT2A | |
| SCHEMBL7522680 | 0.87 | LMNA (0.47) | MAPTTP53ALDH1A1KDM4EKMT2A | |
| SCHEMBL14644351 | 0.87 | MEN1 (0.41) | MAPTTP53ALDH1A1KDM4EKMT2A | |
| SCHEMBL7517813 | 0.86 | KDM4E (0.51) | MAPTTP53ALDH1A1KDM4EKMT2A | |
| SCHEMBL7514951 | 0.86 | HDAC1 (0.51) | TP53ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL7516175 | 0.85 | NPC1 (0.48) | MAPTTP53ALDH1A1KMT2AHPGD | |
| SCHEMBL7516805 | 0.85 | BACE1 (0.47) | MAPTALDH1A1KDM4EKMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018066-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | Schering Corporation & Pharmacopeia Drug Discovery Inc. (US) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018066-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | MAPT 169/4885TP53 1158/4885ALDH1A1 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.